DC Vaccination for Post-remission Therapy in AML

Inclusion Criteria: * Diagnosis of Acute Myeloid Leukemia (AML) * Age 18 - 75 years * Morphologic remission (CR) with or without hematological recovery (CRi) following induction chemotherapy * WT1 with or without PRAME positivity by qPCR * Negative pregnancy test in women of childbearing potential (within 7 days before the first vaccination). Women of childbearing potential and sexually active male participants must use reliable methods of contraception during the whole treatment period and 3 months after the last trial drug dose * Negative HIV 1 and 2 test, Hepatitis B and C test and negative Syphilis test at screening * Informed consent signed prior to any trial related activities Exclusion Criteria: * Patients suitable for allogeneic stem cell transplantation * AML M3 (acute promyelocytic leukemia) * Patients not in complete remission (CR or CRi), bone marrow blast count ≥ 5 % * Active immunodeficiency syndromes * Concurrent active second malignancy other than non-melanoma skin cancers * Clinically relevant autoimmune disease * Prior immunotherapy * Severe organ dysfunction precluding the apheresis procedure: * Creatinine \> 200 mmol/l * Bilirubin, ALAT and ASAT \> 3 x upper normal limit * Respiratory insufficiency with pO2 \< 60 mmHg * Clinically relevant coronary heart disease of ventricular arrhythmia, congestive heart failure \> grade II NYHA * Recent cerebral hemorrhage * Known allergies to substances used in the generation of DCs * Other severe acute or chronic medical psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or the administration of the investigational product * Use of corticosteroids * Active CMV infection (Antibody-positivity due to previous, now inactive infection is accepted) * Inability to comply with the trial protocol * Participation in other clinical trials that, according to the investigator's discretion, may interfere with this trial